Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

---

Copy For Citation

Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., ...More

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol.321, no.2, pp.175-187, 2019 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 321 Issue: 2
• Publication Date: 2019
• Doi Number: 10.1001/jama.2018.20588
• Journal Name: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.175-187
• Karadeniz Technical University Affiliated: Yes

Abstract

IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.